MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Treprostinil

Search medical newsFind research, conditions and clinical updates
  • Home
  • Treprostinil
Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials
Posted innews Respiratory

Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials

Posted by By MedXY 09/28/2026
Combined analysis of the TETON-1 and TETON-2 trials confirms inhaled treprostinil significantly slows lung function decline, reduces clinical worsening and exacerbations, and improves quality of life in idiopathic pulmonary fibrosis over one year.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Nurse Practitioner-Led Pathway Slashes Specialist Wait Times by 75% for High-Risk Liver Disease Patients
  • Pain Perception in Parkinson’s Disease: Insights from Patient Narratives to Improve Care
  • Comparing Piezosurgery and Rotary Burs in Aesthetic Crown Lengthening: A Split-Mouth Randomised Trial
  • Ruzaltatug Rezetecan Versus Chemotherapy for EGFR-Mutated Advanced NSCLC Post-EGFR TKI Therapy: Interim Phase 3 HERON-Lung01 Analysis
  • Low-Level Pyuria and Antibiotic Prescribing for Suspected Urinary Tract Infection in Children
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top